智通财经APP获悉，和黄医药(00013)早盘涨近7%，截至发稿，涨4.28%，报21.95港元，成交额6343.94万港元。
消息面上，和黄医药发布公告，和黄医药自主研发的化合物赛沃替尼 (savolitinib)、HMPL-306 (ranosidenib)、呋喹替尼(fruquintinib)和索凡替尼(surufatinib)的数项研究的最新及更新后的数据将于2025年5月30日至6月3日在美国芝加哥召开的2025年美国临床肿瘤学会(ASCO)年会上公布。
兴业证券此前发布研报称，和黄医药旗下呋喹替尼海外销售增速超指引，拉动公司整体业绩增长，该产品目前已在中国、美国、欧盟、日本等多个市场获批，并且已纳入 NCCN指南(美国国立综合癌症网络指南)的3L结直肠癌治疗推荐、ESMO指南(欧洲肿瘤内科学会指南)的3L及以上结直肠癌治疗推荐，有望进一步提升市场占有率。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.